title: Osteoconductive properties of β-tricalcium phosphate matrix, polylactic and polyglycolic acid gel, and calcium phosphate cement in bone defects.
abstract: Extensive bone defects in maxillofacial region can be corrected with autogenous grafts; otherwise, the disadvantages of the therapeutics modality take the research for new bone substitutes. The aim of the study was to evaluate and compare the osteoconductive properties of 3 commercial available biomaterials. A total of 30 calvarial defects (5-mm diameter) were randomly divided into 5 treatment groups, with a total of 6 defects per treatment group (n = 6). The treatment groups were as follows: 500 to 1000 μm β-tricalcium phosphate (β-TCP), polylactic and polyglycolic acid (PL/PG) gel, calcium phosphate cement, untreated control, and autograft control. The evaluations were based on histomorphometric analysis at 60 postoperative days. The results have shown that β-TCP and autograft control supported bone formation at 60 postoperative days. β-Tricalcium phosphate showed the highest amount of mineralized area per total area and statistically significant compared with PL/PG, calcium phosphate cement, and untreated control groups. The PL/PG gel does not have osteoconductive properties and performed similar to empty control. Calcium phosphate cement showed higher number of multinucleated giant cells around the sites of the biomaterial and showed newly formed bone only at the edges of the biomaterial, without bone formation within the biomaterial. The findings presented herein indicate that bone formation reached a maximum level when rat calvarial defects were filled with β-TCP at 60 postoperative days. Further studies should be conducted with β-TCP to understand the potential of this biomaterial in bone regeneration.
authors.affiliation: Department of Surgery and Integrated Clinic, Araçatuba Dental School, UNESP-Univ Estadual Paulista, São Paulo, Brazil. eloa@foa.unesp.br
authors.forename: Eloá R
authors.initials: ER
authors.lastname: Luvizuto
authors.forename: Thallita P
authors.initials: TP
authors.lastname: Queiroz
authors.forename: Rogério
authors.initials: R
authors.lastname: Margonar
authors.forename: Sônia R
authors.initials: SR
authors.lastname: Panzarini
authors.forename: Eduardo
authors.initials: E
authors.lastname: Hochuli-Vieira
authors.forename: Tetuo
authors.initials: T
authors.lastname: Okamoto
authors.forename: Roberta
authors.initials: R
authors.lastname: Okamoto
mesh_terms: D000818:Animals; D001861:Bone Regeneration / Q000187:drug effects*; D018786:Bone Substitutes / Q000494:pharmacology*; D002130:Calcium Phosphates / Q000494:pharmacology*; D019344:Lactic Acid / Q000494:pharmacology*; D011091:Polyesters; D011100:Polyglycolic Acid / Q000494:pharmacology*; D011108:Polymers / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012886:Skull / Q000187:drug effects* / Q000473:pathology / Q000601:surgery*
chemical_list: D018786:Bone Substitutes; D002130:Calcium Phosphates; D011091:Polyesters; D011108:Polymers; C485817:beta-tricalcium phosphate; D011100:Polyglycolic Acid; D019344:Lactic Acid; C033616:poly(lactide); C020243:calcium phosphate